| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb9c6b40161bafe7bd55f0b4defcea04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_676b80da7ac92b84e447a83fb1630ae1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-912
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5743
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-11001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2013-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef78d5d8de8f22cd3fdfa09f58bd671d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f6cf8824c765873fd9753e2ebf4407c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_658f1cb5d67a709fee85ada5eea2e80a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66120563ef0fec7c84e4a58bc61b1b55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1ee09eea2957dc13d880291364aafef |
| publicationDate |
2014-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2014378469-A1 |
| titleOfInvention |
Lkb1/stk11 deletion in melanoma and related methods |
| abstract |
LKB1 mutation status and/or expression, YES expression and phosphorylation level; and/or CD24 expression are employed to predict melanoma prognosis and response to therapeutics. Inhibitors (including targeted inhibitors) of SRC family kinases (especially YES) are employed to treat melanoma. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017035116-A1 |
| priorityDate |
2012-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |